As cannabis legalization expands, driving under the influence of cannabis has become a significant public safety concern. Unlike alcohol, where the relationship between blood concentration and impairment is well-established, cannabis presents unique challenges for both researchers and law enforcement. Here's what the science actually shows.
The evidence that cannabis impairs driving-relevant skills is unambiguous. THC affects the brain regions responsible for reaction time, divided attention, tracking ability, and decision-making — all critical for safe driving. A 2012 meta-analysis of 66 studies found that cannabis use was associated with a near-doubling of crash risk (OR 1.92). A 2016 study found cannabis-positive drivers were 1.25 times more likely to be involved in a crash.
However, cannabis impairment is more complex than alcohol impairment in several important ways:
Unlike alcohol, where blood alcohol concentration (BAC) reliably predicts impairment, blood THC levels are a poor predictor of driving impairment. THC distributes rapidly into fatty tissues, so blood levels drop quickly even as impairment persists. Chronic users can have high blood THC levels with minimal impairment due to tolerance. Occasional users can be significantly impaired at relatively low blood levels. This makes per se THC limits (like the 5ng/mL limit in some states) scientifically problematic.
Daily cannabis users develop substantial tolerance to the psychomotor effects of THC. Studies consistently show that experienced users perform better on driving simulations after cannabis use than occasional users at the same dose. This does not mean experienced users are safe to drive — it means impairment is highly individual and dose-dependent.
The combination of cannabis and alcohol produces greater impairment than either alone — a synergistic effect. A 2015 study found that drivers who combined cannabis and alcohol had crash risk 23 times higher than sober drivers, compared to 7 times for alcohol alone and 2 times for cannabis alone. This combination is particularly dangerous.
A 2020 randomized controlled trial by Arkell et al. — the first to specifically examine CBD and driving — found that CBD did not impair driving performance on a standardized road test. Participants who received CBD performed identically to placebo. This is consistent with CBD's mechanism of action, which does not involve CB1 receptor activation in motor control regions.
This is one of the most practically important questions, and the answer depends heavily on dose, route of administration, and individual tolerance.
Note: These are general estimates. Individual variation is significant. When in doubt, do not drive.
Law enforcement faces a genuine challenge: there is no cannabis equivalent of the breathalyzer. Current roadside tests include field sobriety tests (subjective), oral fluid tests (detect recent use but not impairment), and blood tests (detect THC but not impairment). All have significant limitations.
Urine tests — commonly used for employment screening — detect THC metabolites that can persist for weeks after use in chronic users. A positive urine test says nothing about current impairment. This creates both false positives (chronic users who are not impaired) and false negatives (occasional users who are impaired but have already cleared THC from urine).
Research into more reliable impairment detection — including eye-tracking technology, cognitive apps, and breath-based THC detection — is ongoing but has not yet produced a validated roadside tool.
Cannabis impairs driving — this is not in dispute. The complexity lies in quantifying that impairment and detecting it reliably, which remains an unsolved scientific and legal challenge. For medical cannabis patients, the practical guidance is straightforward: treat cannabis like alcohol when it comes to driving. If you've used THC-containing cannabis, don't drive. Plan ahead. CBD-only products are the exception — current evidence suggests they do not impair driving performance.